

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**LEPU SCIENTECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.\***

**樂普心泰醫療科技(上海)股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 2291)**

## **INSIDE INFORMATION POSITIVE PROFIT ALERT**

This announcement is made by LEPU SciencTech Medical Technology (Shanghai) Co., Ltd.\* (the “**Company**”) and its subsidiaries (collectively, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the review of the Group’s preliminary unaudited consolidated management accounts for the year ended December 31, 2023 (the “**Reporting Period**”), the Group is expected to record a net profit attributable to owners of the Company ranging from approximately RMB140 million to approximately RMB160 million, as compared with a loss attributable to owners of the Company of RMB19.8 million for the year ended December 31, 2022. It is estimated that the non-IFRS profit is ranging from approximately RMB160 million to approximately RMB180 million as compared with that of approximately RMB111.1 million for the year ended December 31, 2022.

Based on currently available information, the expected increase in net profit attributable to the Shareholders was mainly due to the followings:

- (1) the sales volume of the Group’s last generation of nitinol occluder products during the Reporting Period increased significantly compared with the year ended December 31, 2022. This growth was driven by the Group’s forward-looking strategic mindset in Research and Development (“**R&D**”), strong marketing capabilities, effective academic promotion and extensive distributor network, which further increased the sales volume of such products in the market; and
- (2) in view of the Group’s consistent the R&D innovation strategy, (i) the MemoSorb® full-biodegradable polymer-based occluder systems of which the Center for Drug Evaluation of the National Medical Products Administration of the PRC (“**CDE**”) registration certificate was obtained in February 2022 and (ii) the MemoSorb® biodegradable patent foramen ovale occluder of which the CDE registration certificate was obtained in September 2023, both being the Group’s innovative products, have achieved better sales results during the Reporting Period as compared to the year ended December 31, 2022.

The Company believes that the Group will not only maintain but also expand its robust business performance, aiming to deliver even better returns to the Shareholders in 2024.

As the Group's consolidated financial results for the Reporting Period has not yet been finalised and unaudited, the information contained in this announcement is based on information that is currently available to the Board and the preliminary unaudited consolidated management accounts of the Group for the Reporting Period which have not yet been reviewed by the Company's audit committee. The audited consolidated financial results of the Group for the Reporting Period, which may be subject to adjustment(s) and which may differ from the information contained in this announcement, are expected to be published before the end of March 2024.

**The Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.\***  
樂普心泰醫療科技(上海)股份有限公司  
**Ms. Chen Juan**  
*Chairman of the Board and Executive Director*

Shanghai, the People's Republic of China  
March 19, 2024

*As at the date of this announcement, the Board comprises Ms. Chen Juan as executive Director, Ms. Zhang Yuxin, Mr. Fu Shan and Mr. Zheng Guorui as non-executive Directors, and Ms. Chan Ka Lai Vanessa, Mr. Zheng Yufeng, and Mr. Liu Daozhi as independent non-executive Directors.*

\* *The Company is a registered non-Hong Kong company as defined under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and it is registered under its Chinese name and under the English name "LEPU ScienTech Medical Technology (Shanghai) Co., Ltd."*